In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
Bill Anderson has been named the new chief executive of German life sciences major Bayer. 9 February 2023
Pharmaceutical
From July 1 this year in Australia, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorized psychiatrists for the treatment of certain mental health conditions. 9 February 2023
Pharmaceutical
With analysts forecasting revenues to exceed $11 billion, British pharma major AstraZeneca delivered as expected in the final quarter, taking in $11.3 billion, making $44.3 billion for the full year. 9 February 2023
Biosimilars
Icelandic firm Alvotech and marketing partner German drugmaker STADA Arzneimittel today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab). 9 February 2023
Biotechnology
Belgian biotech Galapagos’ shares were down almost 10% at 36.73 euros this morning, after it revealed that top-line Phase III results of its already commercialized JAK inhibitor Jyseleca (filgotinib) fell short in the induction cohorts of a Crohn's disease trial. 9 February 2023
Biotechnology
French drugmaker Sanofi has announced the availability of its new Pompe disease drug Nexviadyme (avalglucosidase alfa) on the UK’s National Health Service (NHS). 8 February 2023
Biotechnology
US neurological diseases specialist Ovid Therapeutics is expanding its medical and development team with the respective appointments of industry veterans, Dr Manoj Malhotra as its chief medical officer (CMO) and Dr Toshiya Nishi as its head of epilepsy research. 8 February 2023
Biotechnology
The European Commission (EC) marketing authorization (MA) that was granted in December to US biotech Atara Biotherapies for Ebvallo (tabelecleucel) has been transferred to privately French drugmaker Pierre Fabre. 8 February 2023
Generics
Teva Pharmaceutical took in $3.9 billion in revenues in the fourth quarter, around what the majority of analysts had forecast, making for annual sales of $14.9 billion. 8 February 2023
Pharmaceutical
Britain’s AstraZeneca has secured a new European approval for heart med Forxiga (dapagliflozin), an innovative medicine known in the USA as Farxiga. 8 February 2023
Pharmaceutical
Relief Therapeutics has decided to voluntarily withdraw its planned initial public offering (IPO), the Swiss biopharma company announced today, when its shares dipped 1%. 8 February 2023
Biotechnology
US biopharma Vertex Pharmaceuticals has reported its fourth-quarter and full-year financial results. 8 February 2023
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, today released financial results for the fourth-quarter and full-year 2022. 8 February 2023
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued draft guidance, saying that it has not recommended the diabetes drug Jardiance (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction for use on the National Health Service (NHS). 8 February 2023
Pharmaceutical
Belgian drug major UCB’s shares were up 2% at 77.70 euros this morning, on the news that Fintepla (fenfluramine) oral solution has been approved by the European Commission for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. 8 February 2023
Generics
The number of clinical trials of drugs in Russia in 2022 significantly declined, according to latest data from the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 8 February 2023
Biotechnology
Industry analyst GlobalData has released research indicating that sales of COVID-19 vaccines are likely to decline significantly in coming years. 7 February 2023
Biotechnology
Boston, USA-based Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, is $62 million richer. 7 February 2023
Pharmaceutical
The Russian pharmaceutical market has generally withstood the pressure of sanctions from West, as foreign companies stopped supplying only 8% of drug names to Russia, reports The Pharma Letter’s local correspondent. 7 February 2023
Biosimilars
Róbert Wessman, founder and chairman of Icelandic biosimilars company Alvotech and investment fund Aztiq, offers his vision for affordable global healthcare in an Expert View piece. 7 February 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze